Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
02. Dezember 2024 08:00 ET
|
Hepion Pharmaceuticals, Inc.
Transaction Creates Opportunity to Share in Potential Upside of Pharma Two B’s Late-Clinical Stage Candidate to Treat Parkinson’s Disease Hepion’s Board Unanimously Recommends Shareholders Approve...
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger
11. November 2024 08:00 ET
|
Hepion Pharmaceuticals, Inc.
KIRYAT ONO, ISRAEL and EDISON, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Pharma Two B Ltd. (“Pharma Two B”), a late-clinical stage company that is developing P2B001, an innovative combination product...
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger
04. September 2024 09:25 ET
|
Hepion Pharmaceuticals, Inc.
KIRYAT ONO, ISRAEL and EDISON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Pharma Two B Ltd. (“Pharma Two B”), a late-clinical stage company that is developing P2B001, an innovative combination product...
Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement
22. Juli 2024 08:00 ET
|
Hepion Pharmaceuticals, Inc.
Pharma Two B Ltd. (“Pharma Two B”) has entered into a merger agreement with Hepion Pharmaceuticals, Inc. (“Hepion”) (Nasdaq: HEPA)Immediately upon completion of the merger, current Pharma Two B...
Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial
19. April 2024 16:30 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic...
Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell
06. März 2024 08:30 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on therapeutic drug development for the treatment of...
Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds
16. Februar 2024 08:00 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial intelligence assisted therapeutic drug...
Hepion Pharmaceuticals to Present at NASH-TAG 2024
03. Januar 2024 17:15 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes
07. Dezember 2023 08:00 ET
|
Hepion Pharmaceuticals, Inc.
Restructuring program purpose is to preserve capital and optimize clinical development program Management plans to continue to evaluate its Phase 2b ASCEND-NASH clinical trial taking in account...
Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit
28. November 2023 16:15 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...